ClinicalTrials.gg
CompletedNCT00651742Updated Sep 19, 2024Results posted

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

A Phase 2 interventional study of S-1 in Locally Advanced or Metastatic Pancreatic Cancer, sponsored by Taiho Oncology, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Jan 2006, registered Mar 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tegafur in Pancreatic Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Tegafur · Pancreatic Neoplasms.

Enrollment
25th of 25
28 · median 60
Started
2006
with 1 other
Phase 2
21 of 26
2 open now
Registered
6th of 26
by date
Lead sponsor
2 of 26
Taiho Oncology, Inc.

Among the 26 studies testing tegafur in Pancreatic Neoplasms, this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is one of 21 in phase 2, and was the 6th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 26 studies testing tegafur in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tegafur

Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tegafur in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether S-1 is effective in slowing tumor activity in participants with locally advanced or metastatic pancreatic cancer who have not had chemotherapy. The study is also looking at the safety of S-1.

Read the detailed description

Locally advanced or metastatic pancreatic cancer is relatively unresponsive to chemotherapy. This is true for the nucleoside analogue gemcitabine, with a response rate of approximately 10%, as well as for 5-fluorouracil (5-FU). Even when gemcitabine is combined with other chemotherapeutic drugs or biological agents, the overall tumor response rate remains basically unchanged. S-1 is a new generation oral fluoropyrimidine that combines Tegafur (5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione [FT]), an oral prodrug of 5-FU, with two modulators, Gimeracil (5-chloro-2,4-dihydroxypyridine [CDHP]), which inhibits 5-FU degradation by dihydropyrimidine dehydrogenase (DPD) inhibition, and Oteracil potassium (Oxo), which inhibits 5-FU phosphorylation in the digestive tract. This combination of 3 compounds is designed to achieve enhanced antitumor activity while decreasing gastrointestinal toxicity.

03

Conditions studied

  • Locally Advanced or Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written .
  2. Has or cytologically confirmed locally advanced, unresectable or adenocarcinoma of the pancreas not amenable to curative radiotherapy or surgery.
  3. Has as defined by (RECIST) criteria (ie, lesions that can be accurately measured in at least one dimension with the longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm using spiral computed tomography [CT] scan).
  4. Is able to take medications orally.
  5. Is 18 years of age or older.
  6. Has a Performance Status (KPS) ≥ 70%.
  7. Has a of ≥ 12 weeks.
  8. Has adequate organ function as defined by the following criteria:

    1. Transaminases (SGOT) and ALT (SGPT) ≤ 2.5 times the (ULN). If liver function abnormalities are due to underlying liver metastasis, then AST (SGOT) and ALT (SGPT) may be ≤ 5 times ULN.
    2. Total serum ≤ 3.0 times ULN (if due to underlying liver metastasis, then total bilirubin may be ≤ 5 times ULN).
    3. Absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International Units [IU]).
    4. count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).
    5. value ≥ 9.0 g/dL.
    6. Calculated ≥ 60 mL/min (based on serum creatinine) (Cockcroft-Gault85 formula)
  9. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has had treatment with any of the following within the specified time frame prior to study drug administration:

    1. Any prior anticancer chemotherapy.
    2. Radiation therapy to a target lesion unless there was evidence of PD after radiotherapy (and this target lesion must not be the only site of ).
    3. Any radiotherapy within the previous 3 weeks.
    4. Any agent received either concurrently or within the last 30 days.
    5. Current enrollment in another clinical study with an investigational agent. Patients participating in surveys or observational studies are eligible to participate in this study.
  2. Major surgery within the previous 3 weeks.
  3. Symptomatic not controlled by .
  4. .
  5. Previous or concurrent other than pancreatic cancer except adequately treated carcinoma in-situ of the cervix or non-melanoma skin cancer.
  6. Uncontrolled ascites requiring drainage at least twice a week.
  7. Other serious illness or medical condition(s) including, but not limited to, the following:

    1. Uncontrolled congestive heart failure ( [NYHA] Class III or IV), angina pectoris, arrhythmias, or hypertension.
    2. Active infection.
    3. Known (at time of entry) gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea, present to the extent that it might interfere with oral intake and absorption of study medication.
    4. Poorly controlled diabetes mellitus.
    5. Psychiatric disorder that may interfere with consent and/or protocol compliance.
    6. Known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
    7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
  8. Is receiving a concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:

    1. Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1 activity).
    2. Allopurinol (may diminish S-1 activity).
    3. Phenytoin (S-1 may enhance phenytoin activity).
    4. Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and flucytosine activity).
  9. Is a pregnant or lactating female.
  10. Has known sensitivity to 5-FU.
  11. Is a patient with who refuses to use an adequate means of (including male patients).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    S-1 30 mg/m^2

    Participants received 30 milligrams per meter square (mg/m\^2) of S-1 orally twice daily (BID) for 2 weeks (i.e., Day 1 to 14), followed by 1 week recovery period (i.e., Day 15 to 21; one cycle equaled 21 days), treatment was repeated every 3 weeks until death, progression of disease, occurrence of intolerable side effects, withdrawal of consent, or removal by Investigator, whichever comes first.

    Drug: S-1

Interventions

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.

06

What researchers measure

Primary outcomes

  1. Overall Tumor Response Rate (ORR)

    ORR was defined as the percentage of participants with objective evidence of partial response (PR) or complete response (CR) and was based on the best overall response across all cycles for each participant. Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST). For target lesions response, CR was defined as the disappearance of all target lesions for at least 3 weeks and PR was defined as at least a 30% reduction in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum of the longest diameters for at least 6 weeks. For non-target lesions, CR was defined the disappearance of all non-target lesions and normalization of tumor marker level for at least 6 weeks.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with objective evidence of CR, PR or stable disease (SD) determined according to RECIST. For target lesions, stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as a reference the smallest sum of the longest diameters since the treatment started for at least 6 weeks. For non-target lesions, stable disease was defined a persistence of greater than or equal to (\>=) 1 non-target lesions and/or maintenance of tumor marker level above the normal limits for at least 6 weeks.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

  2. Duration of Response (DR)

    DR was calculated as date of first progressive disease (PD) or death, date after the first response of CR or PR minus date of first CR or PR plus 1. Participants who did not die and were without progressive disease were censored at last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

  3. Time to Tumor Progression (TTP)

    TTP was calculated as date of first PD minus date of first dose of study medication plus 1. Participants without progressive disease were censored at last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

  4. Overall Survival (OS)

    OS was calculated as date of death minus date of first dose of study medication plus 1. In the absence of death confirmation, OS was censored at the date of last study follow-up. Analysis was performed by Kaplan-Meier method.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

  5. Progression-free Survival (PFS)

    PFS was defined as date of first PD or date of death minus date of first dose of study medication plus 1. Participants who did not die and were without PD were censored at their last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

    Time frame: From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months

  6. Number of Participants With Karnofsky Performance Status (KPS) Score - Shift From Baseline Score to Final Assessment Score

    KPS classified participant's as per their functional impairment. The KPS ranged from 0percent (%) to 100%, (100= no signs of disease, 90% = few symptoms or signs of disease, 80%=some symptoms or signs, 70% = not capable of normal activity or work, 60% = can take care of most personal requirements, 50% = requires frequent medical care, 40% = disabled, 30% = severely disabled, hospital admission indicated but no risk of death, 20% = very ill, requires supportive measures or treatment, 10% = moribund, rapidly progressive fatal disease processes, and 0% = death), where higher values represented better outcomes. Participants with baseline KPS \>=70% were included in study. Final assessment was the participant's last assessment. Participants with available data were only presented in the below data table.

    Time frame: Baseline, at end of treatment (up to 2 years 5 months)

  7. Change From Baseline in Pain Intensity

    Pain intensity was graded from 0 (least possible pain) to 100 (worst possible pain) on a visual analog scale (VAS). The higher score on VAS scale indicated more pain. Final assessment was the last assessment of participant's.

    Time frame: Baseline, at end of treatment (up to 2 years 5 months)

  8. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)

    An AE was defined as any untoward medical event in a participants administered any dose of a study medication which may or may not have a causal relationship with the use of the study medication. An SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

    Time frame: From the first dose of study medication up to 30 days after the last dose of study medication, or until additional antitumor therapy had been introduced, whichever came first (approximately up to 2 years 6 months)

07

Results

Posted Dec 10, 2021
Limitations and caveats
Since the pre-defined tumor response futility criteria was not exceeded in Stage 1, participant enrollment for Stage 2 was not conducted, as pre-planned in the protocol.

Participant flow

The study was conducted at 9 centers in the Germany between 09-January-2006 to 08-July-2008.

Participant flow — Overall Study
MilestoneS-1 30 mg/m^2
Started28
Treated27
Efficacy analysis per investigator21
Efficacy analysis per independent reader25
Completed0
Not completed28
Withdrew: Objective disease progression22
Withdrew: Toxicity3
Withdrew: Investigator judgment1
Withdrew: Withdrawal of consent1
Withdrew: Enrolled but not treated1

Outcome measures

PrimaryOverall Tumor Response Rate (ORR)

ORR was defined as the percentage of participants with objective evidence of partial response (PR) or complete response (CR) and was based on the best overall response across all cycles for each participant. Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST). For target lesions response, CR was defined as the disappearance of all target lesions for at least 3 weeks and PR was defined as at least a 30% reduction in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum of the longest diameters for at least 6 weeks. For non-target lesions, CR was defined the disappearance of all non-target lesions and normalization of tumor marker level for at least 6 weeks.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Number · percentage of participants
Overall Tumor Response Rate (ORR)
percentage of participantsS-1 30 mg/m^2
Independent Assessment4.0 (0.1 to 20.4)
Investigator Assessment9.5 (1.2 to 30.4)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants with objective evidence of CR, PR or stable disease (SD) determined according to RECIST. For target lesions, stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as a reference the smallest sum of the longest diameters since the treatment started for at least 6 weeks. For non-target lesions, stable disease was defined a persistence of greater than or equal to (\>=) 1 non-target lesions and/or maintenance of tumor marker level above the normal limits for at least 6 weeks.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsS-1 30 mg/m^2
Independent Assessment68.0 (46.5 to 85.1)
Investigator Assessment76.2 (52.8 to 91.8)
SecondaryDuration of Response (DR)

DR was calculated as date of first progressive disease (PD) or death, date after the first response of CR or PR minus date of first CR or PR plus 1. Participants who did not die and were without progressive disease were censored at last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Median · months
Duration of Response (DR)
monthsS-1 30 mg/m^2
Independent Assessment7.4 (NA to NA)
Investigator AssessmentNA (2.8 to NA)
SecondaryTime to Tumor Progression (TTP)

TTP was calculated as date of first PD minus date of first dose of study medication plus 1. Participants without progressive disease were censored at last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Median · months
Time to Tumor Progression (TTP)
monthsS-1 30 mg/m^2
Independent Assessment3.5 (1.6 to 5.5)
Investigator Assessment3.5 (2.5 to 5.3)
SecondaryOverall Survival (OS)

OS was calculated as date of death minus date of first dose of study medication plus 1. In the absence of death confirmation, OS was censored at the date of last study follow-up. Analysis was performed by Kaplan-Meier method.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Median · months
Overall Survival (OS)
monthsS-1 30 mg/m^2
Overall Survival (OS)9.1 (4.7 to 11.2)
SecondaryProgression-free Survival (PFS)

PFS was defined as date of first PD or date of death minus date of first dose of study medication plus 1. Participants who did not die and were without PD were censored at their last evaluable tumor response assessment. Analysis was performed by Kaplan-Meier method.

Time frame:
From first dose of study medication until disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 2 years 5 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsS-1 30 mg/m^2
Independent Assessment3.5 (1.6 to 5.5)
Investigator Assessment3.5 (2.5 to 5.3)
SecondaryNumber of Participants With Karnofsky Performance Status (KPS) Score - Shift From Baseline Score to Final Assessment Score

KPS classified participant's as per their functional impairment. The KPS ranged from 0percent (%) to 100%, (100= no signs of disease, 90% = few symptoms or signs of disease, 80%=some symptoms or signs, 70% = not capable of normal activity or work, 60% = can take care of most personal requirements, 50% = requires frequent medical care, 40% = disabled, 30% = severely disabled, hospital admission indicated but no risk of death, 20% = very ill, requires supportive measures or treatment, 10% = moribund, rapidly progressive fatal disease processes, and 0% = death), where higher values represented better outcomes. Participants with baseline KPS \>=70% were included in study. Final assessment was the participant's last assessment. Participants with available data were only presented in the below data table.

Time frame:
Baseline, at end of treatment (up to 2 years 5 months)
Reported as:
Count of participants · Participants
Number of Participants With Karnofsky Performance Status (KPS) Score - Shift From Baseline Score to Final Assessment Score
ParticipantsS-1 30 mg/m^2
Baseline score 100% shift to Final assessment score 100%6
Baseline score 100% shift to Final assessment score 90%7
Baseline score 100% shift to Final assessment score 70%1
Baseline score 100% shift to Final assessment score 0%1
Baseline score 90% shift to Final assessment score 90%1
Baseline score 90% shift to Final assessment score 80%3
Baseline score 90% shift to Final assessment score 70%1
Baseline score 90% shift to Final assessment score 60%1
Baseline score 90% shift to Final assessment score 0%2
Baseline score 80% shift to Final assessment score 80%1
Baseline score 80% shift to Final assessment score 0%2
Baseline score 70% shift to Final assessment score 0%1
SecondaryChange From Baseline in Pain Intensity

Pain intensity was graded from 0 (least possible pain) to 100 (worst possible pain) on a visual analog scale (VAS). The higher score on VAS scale indicated more pain. Final assessment was the last assessment of participant's.

Time frame:
Baseline, at end of treatment (up to 2 years 5 months)
Reported as:
Mean · millimeters (mm)
Change From Baseline in Pain Intensity
millimeters (mm)S-1 30 mg/m^2
Change From Baseline in Pain Intensity-6.47 ± 27.619
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)

An AE was defined as any untoward medical event in a participants administered any dose of a study medication which may or may not have a causal relationship with the use of the study medication. An SAE was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

Time frame:
From the first dose of study medication up to 30 days after the last dose of study medication, or until additional antitumor therapy had been introduced, whichever came first (approximately up to 2 years 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)
ParticipantsS-1 30 mg/m^2
At Least 1 AE25
At Least 1 SAE15

Adverse events

Collected over From the first dose of study medication up to 30 days after the last dose of study medication, or until additional antitumor therapy had been introduced, whichever came first (approximately up to 2 years 6 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-1 30 mg/m^224/27 (88.9%)15/27 (55.6%)25/27 (92.6%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventS-1 30 mg/m^2
Abdominal painGastrointestinal disorders4/27
Disease progressionGeneral disorders4/27
DiarrhoeaGastrointestinal disorders2/27
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/27
AscitesGastrointestinal disorders1/27
ConstipationGastrointestinal disorders1/27
Duodenal stenosisGastrointestinal disorders1/27
VomitingGastrointestinal disorders1/27
FatigueGeneral disorders1/27
General physical health deteriorationGeneral disorders1/27
Most frequent other events
Showing 10 of 51
Most frequent other events
EventS-1 30 mg/m^2
NauseaGastrointestinal disorders10/27
FatigueGeneral disorders10/27
DiarrhoeaGastrointestinal disorders9/27
VomitingGastrointestinal disorders9/27
Weight decreasedInvestigations9/27
Abdominal pain upperGastrointestinal disorders7/27
Lacrimation increasedEye disorders6/27
ConstipationGastrointestinal disorders6/27
FlatulenceGastrointestinal disorders5/27
AnorexiaMetabolism and nutrition disorders5/27

Baseline characteristics

Safety population included all participants who had received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)S-1 30 mg/m^2
Mean64.3 ± 10.48
Sex: Female, Male
Sex: Female, Male(Participants)S-1 30 mg/m^2
Female13
Male14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)S-1 30 mg/m^2
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White27
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Jul 2008, 29 months.

Results were first posted in Dec 2021, 13 years 5 months after primary completion. A results delay was requested in Jun 2013.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 29 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 3, 2008
StartActual
Jan 9, 2006
Primary completionActual
Jul 8, 2008
CompletionActual
Jul 8, 2008
Results delay requested
Jun 4, 2013
Results first posted
Dec 10, 2021
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00651742
Collaborators
Quintiles, Inc., United BioSource, LLC
Responsible party
Sponsor
First posted
Apr 3, 2008
Start date
Jan 9, 2006
Primary completion
Jul 8, 2008
Completion
Jul 8, 2008
Results posted
Dec 10, 2021
Last update
Sep 19, 2024

Study contacts

Taiho Central
study director · Taiho Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid

Start the discussion